

## EFFECT OF GHRELIN ON TESTICULAR FUNCTIONS IN STREPTOZOTOCIN INDUCED TYPE 1 DIABETIC RATS

*Maher N. Ibrahim, Ali Kh. Asalah, Dalia I. Abd-Alaleem and Suzan M. M. Moursi*  
Physiology department-Faculty of medicine-Zagazig University

### ABSTRACT

**Background:** Oxidative stress is increased in diabetes mellitus (DM). Ghrelin is a peptide hormone produced by different tissues and its circulating level is decreased in type 1 DM. Recently, it has been shown to have antioxidant properties. **Objective:** This study was designed to investigate the effects of diabetes mellitus on pituitary testicular functions and the role of ghrelin in the modulation of these effects in a rat model of type 1 diabetes mellitus induced by streptozotocin. **Materials and methods:** 32 healthy adult male albino rats of initial body weight 170-195 gm were included. Rats were randomly and equally divided into 4 groups, group (1a): Vehicle treated (control) group, group (1b): Ghrelin treated normal group, group (IIa): STZ-diabetic group and group (IIb): Ghrelin treated diabetic group. Rats were weighed and examined for the serum levels of glucose, insulin, FSH, LH & testosterone levels, epididymal sperm count and motility, testicular malondialdehyde (MDA) level and superoxide dismutase (SOD), catalase (CAT) & glutathione peroxidase (GP<sub>x</sub>) activities and testicular weight(wt) & histopathology. **Results:** STZ-induced diabetes significantly decreased the body wt, testes wt, serum insulin, FSH, LH & testosterone levels, epididymal sperm count & motility and testicular SOD, CAT & GP<sub>x</sub> activities but significantly increased serum glucose & testicular malondialdehyde levels together with deterioration of the testicular histoarchitecture. Moreover, it was found that exogenous administration of ghrelin resulted in a significant recovery of all the above mentioned parameters in the diabetic group, while in the normal group, it was only associated with potentiation of the testicular antioxidant system as well as a significant increase in both the body and testes weights. **Conclusion:** Ghrelin has a potential protective role against diabetes-induced pituitary testicular dysfunction which may be due to its antioxidant properties and maintenance of glucose & insulin homeostasis.

**Key words:** Diabetes, Ghrelin, testicular function, oxidative stress.

### INTRODUCTION

**D**M is the most common chronic metabolic disorder which is characterized by hyperglycemia caused by abnormal insulin production, insulin resistance or often both (1,2). Diabetic patients generally experience sexual abnormalities like sexual dysfunction, impotence and infertility (3, 4).

There are apparently contradictory reports concerning male reproductive parameters in diabetics. While, some investigators detected low serum levels of gonadotropins and testosterone as well as a decrease in sperm count and motility (5,6,7), others reported elevated or unaffected pituitary gonadotrophins and testosterone but with a reduction in their receptors (8). Moreover, some studies reported that diabetic men may represent normal semen parameters, but they have a higher level of damage in sperm nuclear and mitochondrial DNAs (9). In contrast, another study showed that sperm count and concentration were significantly increased in type 1 diabetic subjects while semen volume and sperm motility were significantly decreased (10).

It is indicated that the oxidative stress is more in hyperglycemic state, due to the excessive production of reactive oxygen species (ROS) and

decreased efficiency of anti-oxidant enzyme defenses (11,12). The stability and capacity of the antioxidant defense against ROS during chronic diabetes plays an important role in the outcome of long term complications caused by ROS (13). So, antioxidants may be useful in the treatment of male infertility as reported by many researchers (12,14,15,16).

Ghrelin is a 28-amino-acid peptide initially isolated from human and rat stomach as an endogenous ligand for the growth hormone secretagogue receptor (GHS-R) which acts on the pituitary to stimulate GH release and on the hypothalamus to enhance food intake (17,18). Its circulating plasma level is 100–150 fmol/ml (19) which is reduced in type 1 DM (20). Ghrelin secreting cells have also been identified in pancreas (21), hypothalamus (22), pituitary (23), interstitial Leydig cells and in Sertoli cells (24).

Ghrelin is involved in glucose metabolism, whatever, data regarding ghrelin influence on insulin secretion are still contradictory; both inhibitory (25) and stimulatory effects having been reported (26,27). Furthermore, it has been proposed that ghrelin is an endogenous antioxidant and functions as a free radical scavenger. The antioxidative properties of ghrelin

via increasing of antioxidant enzyme activities and reduction in lipid peroxidation have been reported in preadipocyte cell lines (28), rat ovary (29), liver (30) & gastric injuries (31) and sensorimotor neuropathy (32). Moreover, ghrelin treatment protected against testicular germ cells damage induced by oxidative stress of heat exposure and ischemia reperfusion injury, and this effect may be due to its antioxidant properties (33,34).

This study was designed to investigate the effects of diabetes mellitus on testicular functions and to evaluate the effects of exogenously administered ghrelin in the modulation of these effects in a rat model of type 1 diabetes mellitus induced by streptozotocin treatment. The level of androgenic hormones, sperm quality, testicular histoarchitecture & antioxidant enzyme activities were examined in a trial to clarify possible involved mechanisms.

#### MATERIAL AND METHODS

This study was conducted on 32 healthy adult male albino rats weighing 170-195 gm, were obtained from the animal house of Faculty of Veterinary Medicine- Zagazig University. Rats were kept in steel wire cages (4/cage) in the physiology animal house in Faculty of Medicine - Zagazig University under hygienic conditions. They had free access to water, kept at room temperature and were maintained on a 12 h light/dark cycle. Rats were adapted to the new environment for one week before the experiment going on. All investigations were conducted in accordance with the guiding principles for the care and use of research animals and were approved by the Institutional Research Board.

Rats were randomly divided into four equal groups, group (1a): Vehicle treated (control) group, each rat received every other day for 30 days a single s.c injection of 100 µl saline, group (1b): Ghrelin treated normal group, each rat received every other day for 30 days a single s.c injection of ghrelin (acylated powder form ,Sigma Aldrich Co.-USA) at a dose of 2 nmol/100 µl saline (33), group (IIa): STZ-diabetic group, in which experimental diabetes was induced by an i.p injection of freshly prepared streptozotocin (Sigma Aldrich Co.-USA) at a dose of 60 mg/kg dissolved in saline (35) in overnight fast rats . After 72 hours, fasting glucose level was measured using glucometer (ACCU CHEK, Roche Diagnostics, Germany) and rats with blood glucose levels above 360 mg/dl were included for this study (8) with weekly monitoring of those levels throughout the study. In this group each rat received every other day for 30 days a

single s.c injection of 100 µl saline and group (IIb): Ghrelin treated diabetic group, each rat received every other day for 30 days a single s.c injection of ghrelin at a dose of 2 nmol/100 µl saline (33).

N.B. The dose of ghrelin used in our experiments was comparable with the amounts of ghrelin secreted into the blood during starvation: exogenous administration of 1 nmol of ghrelin is able to induce a significant elevation (2.4 to 2.6-fold increase) in serum levels of total ghrelin 1 h after injection (36), whose magnitude is in the range of that induced by fasting (37).

**Sample collection:** Blood samples were collected from retro-orbital venous plexus 24 hours after the last injection of ghrelin and serum was separated by centrifugation of blood at 3000 rpm for 20 minutes and kept deep frozen at (-20° c) until used to measure serum glucose, insulin, FSH, LH and testosterone levels. After collecting blood samples, laparotomy was conducted after the animals were sacrificed by cervical dislocation under mild ether anesthesia. Testes and epididymes were collected. The epididymes were used for the evaluation of sperm parameters. The testes were weighed then the right one was processed for histopathological studies and the left one was homogenated for biochemical estimations of MDA levels and SOD, GP<sub>x</sub> & CAT activities.

**Preparation of testis homogenate:** The testes were sliced and homogenized in cold 50 mM phosphate buffer (pH 7.0) containing 0.1 mM EDTA to give 10% homogenate (w/v). The homogenates were centrifuged at 1000 r.p.m. for 10 min. The supernatants were separated and used for enzymes activity assays and lipid peroxidation determination (38).

#### Biochemical Analysis

**1) Serum glucose level:** According to *Tietz, (39)* using glucose enzymatic (GOD-PAP) - liquizyme Kits (Biotechnology, Egypt), measured by using spectrophotometer (spectronic 3000 Array, Germany) at 546 nm.

**2) Serum insulin level:** according to *Temple et al. (40)* using KAP1251-INS-EASIA (Enzyme Amplified Sensitivity Immunoassay) Kits (BioSource Europe S.A., Belgium).

**3) Serum FSH level:** according to *Rebar et al. (41)* using Follicle-Stimulating Hormone (FSH) enzyme immunoassay test kit (Catalog Number: BC-1029, BioCheck, Inc 323 Vintage Park Dr. Foster City, CA 94404).

**4) Serum LH level:** according to *Tietz, (39)* using Luteinizing hormone (LH) enzyme immunoassay test kit (Catalog Number: BC-1031, BioCheck, Inc 323 Vintage Park Dr. Foster City, CA 94404).

**5) Serum testosterone level:** according to *Tietz*, (39) using testosterone enzyme immunoassay test kit (Catalog Number: BC-1115, BioCheck, Inc 323 Vintage Park Dr. Foster City, CA 94404).

All the above hormones are measured by using spectrophotometer (spectronic 3000 Array, Germany) at 450 nm.

**6) Testicular antioxidant system evaluation:**

○ Assay of superoxide dismutase (SOD) activity: according to the method described by *Kakkar et al.* (42).

○ Assay of of catalase (CAT) activity: according to the method described by *Luck* (43).

○ Assay of glutathione peroxidase (GP<sub>x</sub>) activity: according to the method described by *Reddy et al.* (44).

○ Assay of MDA level: according to the method described by *Ohkawa et al.* (45).

All are measured by using spectrophotometer (spectronic 3000 Array, Germany) at 560, 240, 430, 535 nm respectively.

**Analysis of sperm parameters:**

The right epididymis of each rat was dissected, removed and minced in 2 ml of Hank's buffer salt solution (HBSS) at 37 °C (8). After 5 min incubation at 37°C, the caudal epididymis sperm was determined using the standard hemocytometric method (46). The percentage of sperm motility was calculated using the number of live sperm cells over the total number of sperm cells (16).

**Histopathological examination:**

Testes from all groups were removed and fixed in Bouin's solution and followed by dehydration in a descending series of ethyl alcohol, were cleared in xylene and embedded in paraffin. Paraffin sections of testes were cut at 5 µm on a rotary microtome, mounted on slides and stained with hematoxylin eosin (H&E) and examined under a light microscope by a blinded pathologist.

**Statistical Analysis:**

The data obtained in the present study were expressed as mean ± SD for quantitative variables and statistically analyzed by using SPSS program (version 18 for windows) (SPSS Inc. Chicago, IL, USA). One way Analysis of variance (ANOVA) was used to compare the results of all examined groups followed by LSD test to compare statistical differences between groups. Paired t. test was used to compare the initial and final body weights. P value <0.05 was considered statistically significant.

**RESULTS**

The present study showed that STZ-induced diabetes significantly decreased the body weight, testes wt, serum insulin, FSH, LH & testosterone levels, epididymal sperm count & motility and testicular SOD, CAT & GP<sub>x</sub> activities but significantly increased serum glucose & testicular MDA levels (p<0.001) (tables 1, 2&3).

Moreover, it was found that exogenous administration of ghrelin to the diabetic group resulted in a significant increase (p<0.001) in the body weight wt, testes wt, serum insulin, LH & testosterone levels, epididymal sperm count & motility and testicular SOD, CAT & GP<sub>x</sub> activities and FSH (p<0.01), but significantly decreased serum glucose& testicular MDA levels in comparison to diabetic untreated group (tables 1, 2&3).

In addition, it was observed that exogenously administered ghrelin to the normal group while significantly (p<0.001) increased in the body wt, testicular SOD, CAT & GP<sub>x</sub> activities and testes wt (p<0.01), it significantly (p<0.001) decreased testicular MDA levels and produced no significant changes in serum glucose, insulin, FSH, LH or testosterone levels or epididymal sperm count & motility in comparison to normal untreated group (tables 1, 2&3).

**Table 1:** Body & testicular weights in all studied groups.

parameter	(n=8)	Group 1a	Group 1b	Group IIa	Group IIb
Initial body wt (gm)	$\bar{X} \pm SD$	183.5 ± 7.8	180.62 ± 5.57	179.12 ± 5.54	182.75 ± 7.9
	P value of LSD		NS <sup>a</sup>	NS <sup>a,b</sup>	NS <sup>a,b,c</sup>
Final body wt (gm)	$\bar{X} \pm SD$	241.75 ± 8.51	268.87 ± 8.85	147.12 ± 9.29	181.25 ± 11.88
	P value of LSD		P < 0.001 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.001 <sup>a,b,c</sup>
	P value of t test	P < 0.001	P < 0.001	P < 0.001	NS
testis wt(gm)	$\bar{X} \pm SD$	1.36 ± 0.11	1.55 ± 0.09	0.93 ± 0.16	1.21 ± 0.11
	P value of LSD		P < 0.01 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.05 <sup>a</sup> , P < 0.001 <sup>b,c</sup>

**Table 2:** Serum glucose, insulin, FSH, LH and testosterone levels in all studied groups.


parameter	(n=8)	Group 1a	Group 1b	Group IIa	Group IIb
Serum glucose (mg/dl)	$\bar{X} \pm SD$	87.57 ± 7.07	81.39 ± 7.40	552.42 ± 28.10	178.08 ± 20.26
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.001 <sup>a,b,c</sup>
Serum insulin(μIU/ml)	$\bar{X} \pm SD$	26.93 ± 3.24	28.74 ± 2.77	7.81 ± 1.26	17.17 ± 2.65
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.001 <sup>a,b,c</sup>
Serum FSH (μIU/ml)	$\bar{X} \pm SD$	0.41 ± 0.07	0.36 ± 0.04	0.25 ± 0.05	0.34 ± 0.02
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.05 <sup>a</sup> , NS <sup>b</sup> , P < 0.01 <sup>c</sup>
Serum LH (μIU/ml)	$\bar{X} \pm SD$	0.41 ± 0.07	0.37 ± 0.05	0.2 ± 0.04	0.33 ± 0.04
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.05 <sup>a</sup> , NS <sup>b</sup> , P < 0.001 <sup>c</sup>
Serum testosterone (ng/ml)	$\bar{X} \pm SD$	5.09 ± 1.06	4.57 ± 0.69	1.74 ± 0.21	3.84 ± 0.72
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.01 <sup>a</sup> , NS <sup>b</sup> , P < 0.001 <sup>c</sup>

**Table 3:** Epididymal sperm count & motility and testicular MDA level, testicular SOD, CAT & GP<sub>x</sub> activities in all studied groups.


parameter	(n=8)	Group 1a	Group 1b	Group IIa	Group IIb
Epididymal sperm count (millions/ml)	$\bar{X} \pm SD$	50.87 ± 4.01	47.5 ± 4.59	21.62 ± 4.74	41.25 ± 5.67
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.001 <sup>a,c</sup> , P < 0.05 <sup>b</sup>
Epididymal sperm motility (%)	$\bar{X} \pm SD$	71.87 ± 5.93	76.25 ± 6.4	28.12 ± 7.03	55 ± 9.25
	P value of LSD		NS <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.001 <sup>a,b,c</sup>
Testicular MDA level (nmol/gm tissue)	$\bar{X} \pm SD$	111.86 ± 7.55	67.02 ± 13.06	197.10 ± 22.85	128.56 ± 8.14
	P value of LSD		P < 0.001 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	P < 0.05 <sup>a</sup> , P < 0.001 <sup>b,c</sup>
Testicular SOD activity (U/mg protein)	$\bar{X} \pm SD$	76.34 ± 7.23	120.72 ± 16.8	37.34 ± 4.99	68.36 ± 9.82
	P value of LSD		P < 0.001 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	NS <sup>a</sup> , P < 0.001 <sup>b,c</sup>
Testicular CAT activity (U/mg protein)	$\bar{X} \pm SD$	19.54 ± 2.46	42.04 ± 4.53	7.52 ± 1.65	16.93 ± 2.17
	P value of LSD		P < 0.001 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	NS <sup>a</sup> , P < 0.001 <sup>b,c</sup>
Testicular GP <sub>x</sub> activity (U/mg protein)	$\bar{X} \pm SD$	24.06 ± 2.4	35.78 ± 2.94	15.68 ± 3.1	23.80 ± 2.68
	P value of LSD		P < 0.001 <sup>a</sup>	P < 0.001 <sup>a,b</sup>	NS <sup>a</sup> , P < 0.001 <sup>b,c</sup>

a = versus group Ia  
c = versus group IIa


b = versus group Ib  
NS = non significant (P > 0.05)




**Photo1:** Photomicrograph of left rat testicular tissue isolated from group 1a showing: Normal testis formed of: 1) uniform seminiferous tubules lined by normal layers of spermatogenic cells up to mature sperm formation (long arrow) 2) basement membrane of normal thickness (short arrow) (H&E x 400)



**Photo2:** Photomicrograph of left rat testicular tissue isolated from group 1b showing: normal seminiferous tubules lined by normal thickness of the basement membrane (H&E x 400)



**Photo 3:** Photomicrograph of of left rat testicular tissue isolated from group IIa showing: 1) variable sized and shaped seminiferous tubules lined by few layers of spermatogenic cells with wide lumina. 2) Marked thickening of the basement membrane. 3) Excessive oedema of the interstitial tissue (interrupted arrow). (H&E x 400)



**Photo 4:** Photomicrograph of of left rat testicular tissue isolated from group IIb showing: 1) seminiferous tubules lined by nearly normal layers of spermatogenic cells with mature sperms 2) the basement membrane of nearly normal thickness. (H&E x 400)

### DISCUSSION

Type 1 DM is associated with many complications including male infertility. Increased lipid peroxidation and the imbalanced carbohydrate metabolism cause impairment of the steroidogenic function of the testis in addition to the cellular and tissue damage (47). This may explain the possible etiologies for increasing cases of infertility among diabetic males (48), and so the balance between oxidant and antioxidant species has been proposed to have an important role in preventing diabetic complications (12).

Ghrelin, a peptide hormone predominantly produced by the stomach and, it is the endogenous ligand for the growth hormone secretagogue receptor (49). Its plasma levels are reduced in type 1 diabetes mellitus (50). Moreover, ghrelin has been reported to exert antioxidant properties (51). Therefore, this study was designed to explore the probable effects of this peptide in modulating the adverse effects of diabetes on testicular function.

In present work, ghrelin administration significantly increased the body weight in both normal and diabetic groups. This is in accordance with the findings of other investigators who reported that ghrelin administration increased body weight of freely fed mature rats (52,53). This effect may be induced by a number of biological responses at the central neuroendocrine level, including stimulation of food intake and adiposity (54,55,56). As both acylated and desacylated ghrelin have been shown to cross the

blood brain barrier (BBB) via either active transport or passive diffusion (57,58). The hypothalamic arcuate nucleus (ARC) is the main site of ghrelin's activity in the central nervous system where ghrelin acts via GHSR-1a to stimulate neurones containing the orexigenic factors neuropeptide Y and agouti related peptide and inhibit neurons producing the anorexigenic peptides pro-opiomelanocortin, cocaine and amphetamine related transcript (59). Neurones in the arcuate nucleus also stimulate orexin-containing neurones in the lateral hypothalamic area to increase appetite (60). The primary effect of ghrelin injections on meal patterns is the decrease of the inter-meal intervals, thus increasing meal number without affecting meal size (61).

In addition to its orexigenic effects, ghrelin plays a role in the regulation of long-term energy homeostasis. Ghrelin increased the preference for fat diets & induced adipogenesis (62) and decreased adipocyte apoptosis (63), lipolysis (64), sympathetic nervous system activity, body temperature, and locomotor activity, therefore, ghrelin plays a role in all aspects of energy homeostasis, tending to promote weight gain (65). In addition to the orexigenic and adipogenic effect of ghrelin, it may also recover the body wt of the diabetic group through the improvement in glucose homeostasis, which was demonstrated in our results.

In the present work, i.p administration of STZ significantly elevated fasting serum glucose

level with a significant concomitant reduction in serum insulin level as reported earlier by *Shrilatha and Muralidhara*, (66). The mechanism of STZ induced DM is probably through the generation of reactive oxygen species (ROS), leading to islet cell destruction (67). In addition, it was found that while exogenous administration of ghrelin resulted in a significant recovery of serum glucose and insulin levels in STZ diabetic rats, it was associated with insignificant alterations of these parameters in the normal control rats.

These results are in agreement with those of some investigators who reported that exogenous administration of ghrelin in low doses resulted in increase in insulin release which may be partly via the increase in intracellular  $Ca^{+2}$  concentration induced by activation of phospholipase C (PLC) (26,68,69).

Also, our results are supported by the findings of *Kerem et al.* (70) who reported that in 90% pancreatectomized rats, acylated ghrelin (AG) administration strongly reduced glucose levels & increased insulin-producing  $\beta$  -cell number together with increased insulin secretion. On the contrary, they found that ghrelin receptor antagonist administration worsens glucose levels and  $\beta$  -cell mass that is in support of the involvement of GHSR1a or of endogenous ghrelin in islet cell survival and function.

However, the results of the present work at variance with those of others who demonstrated that exogenous administration of ghrelin in high doses resulted in a significant increase in blood glucose level associated with a suppression of insulin release via opening of voltage sensitive  $K^{+}$  channels that repolarizes the plasma membrane and closes  $Ca^{2+}$  channels (25,71).

It is well established that chronic hyperglycemia in addition to production of ROS can directly promote an inflammatory state, where the increase in cytokines (IL-6, IL-18, IL-1 and TNF - $\alpha$  ) can lead to destruction of the pancreatic beta cells (72). Interestingly, in the pancreas of STZ-diabetic rats, ghrelin was reported to promote cell proliferation and inhibit cytokines induced apoptotic events (specially by NO) in  $\beta$ -cell lines via Gs  $\alpha$  protein-coupled receptor/adenylyl cyclase/ cAMP/ protein kinase A pathway ( 73,74).

Thus, the correction of hypoinsulinemia and hyperglycemia encountered, in the present study, in STZ diabetic rats by exogenous administration of ghrelin could be attributed to the antioxidant protective effects of this peptide with promotion of  $\beta$  cell proliferation/regeneration (i.e.

increased  $\beta$  cell mass) and increased insulin expression and secretion.

The results of the present work also demonstrated a significant decrease in serum FSH, LH& testosterone levels in STZ-diabetic group in comparison to the normal control group. These results are in line with many investigators who attributed this to interference of diabetes with the hypothalamo-pituitary–testicular axis at multiple levels. They also showed that this impairment was induced by ROS & resulted in a significant decrease in expression of steroidogenic genes pathways (7,75,76,77). However, our results are at variance with those of Idris et al., (8) who reported that plasma testosterone and LH levels were unaffected in diabetic rats while FSH level was remarkably high and, observed that diabetes did not alter the functions of pituitary glands and Leydig cells but affected Sertoli cell functions owing to reduction in FSH receptors. Since Sertoli cells are involved in developing sperm cells and regulating internal environment of seminiferous tubules, reduction in their number decreases spermatogenic output (78).

In fact GnRH-expressing neurons in the hypothalamus express insulin receptors that respond to insulin stimulation by showing an increase in the expression of the transcriptional factor (c-fos), rapidly followed by an increase in the expression of GnRH itself suggesting that hypothalamic GnRH neurons may be directly modulated by insulin (79). Therefore, insulin deficiency in STZ-diabetic rats may reduce the strength of the GnRH impulse and consequently attenuate GnRH dependent pituitary feedforward signaling (6). Herbison, (80) and Soudamani et al. (81) have also shown decreased availability of serum estradiol & catecholamine synthesis at the hypothalamic level in STZ-induced diabetic rats and this in turn leads to decreased GnRH pulse frequency and amplitude.

Moreover, in vitro studies have shown that insulin may act directly on the anterior pituitary in the regulation of gonadotropin release (82), and alterations in the cellular composition of the anterior pituitary could also be involved in some of the diabetes-induced endocrine disruptions, as this gland undergoes increased ROS-induced apoptosis in poorly controlled STZ-diabetic rats (83).

The present study also showed that streptozotocin-induced diabetic rats had poor sperm quality. Epididymal sperm count was significantly low with a significant decrease in sperm motility. These findings are consistent with those of some investigators (8,12,16), but at

variance with those of others who reported that diabetic men may have normal semen parameters, or only a significant decrease in semen volume, but they have a higher level of damage in sperm nuclear and mitochondrial DNA than control individuals (9,84).

Oxidative stress may be one of the possible reasons of the changes in sperm quality observed in the present study in STZ-induced type I DM. The resulting mitochondrial dysfunction impairs spermatogenesis and decreases sperm motility (85). Apart from that, sperm head membrane is also highly sensitive to oxidative stress due to rich polyunsaturated fatty acid content (86). Current situation is worsened by the highly condensed DNA in sperm, where free radicals induce genotoxicity by initiating sperm DNA denaturation and fragmentation with limited DNA repair (87). Another possible reason for low sperm count in STZ-diabetic group is low testicular glucose utilization by Sertoli cell which serve as energy source for sperm development (88) beside the decrease in sex hormones, another factor that can regulate spermatogenesis (8).

The present findings showed that exogenous ghrelin administration resulted in a significant recovery of FSH, LH & testosterone levels together with a marked restoration in epididymal sperm count and motility towards the control levels in the STZ- induced diabetic group. These protective effects of this peptide may be due to its free radical scavenging properties, which were proved in the present study as it was found that while STZ-induced diabetes resulted in a significant elevation of the testicular MDA level accompanied with a significant reduction of testicular antioxidant enzymes CAT, GP<sub>x</sub> and SOD activities, exogenous administration of ghrelin to these diabetic animals resulted in a significant recovery of all these parameters.

Since oxidative stress plays a key role in pathogenesis of DM induced male reproductive defects (16,89), it seems that ghrelin possibly via its antioxidant properties protects the testicular germ cells against the adverse effects of DM, accelerates testicular regenerative processes in this condition and enhances the rate of total sperm motility & the percentage of sperm forward progressive movement that may be also attributed to increased intracellular Ca<sup>+2</sup> level after binding of ghrelin to its specific receptor (90,91).

The results of the present study also showed that STZ-induced diabetes significantly decreased the testicular weight in comparison to the normal control group. Moreover, histopathologically, testicular sections showed

interstitial edema together with variable sized and shaped seminiferous tubules lined by few layers of spermatogenic cells with wide lumina and marked thickening of the basement membrane in STZ-diabetic group. This is in accordance with the findings of Nah *et al.* (7); Idris *et al.* (8) & Kyathanahalli *et al.* (92).

Those adverse effects of diabetes on the testicular wt and architecture are likely due to low serum levels of both testosterone hormone which is the major regulator of normal growth of reproductive organs and FSH hormone, since this hormone is essential to stimulate Sertoli cells to synthesize and secrete androgen-binding protein, which is important to bind testosterone that is required for terminal differentiation of spermatids (93). Also, decreased FSH level would also decrease the production of the stem cell factor (SCF). This factor is a Sertoli cell product that has been involved in Leydig cell development and survival and is acting as a survival factor for the different cell types in the seminiferous epithelium such as spermatogonia in adult rats (94). Furthermore, the physical alterations observed in the present study possibly resulted from testicular local reaction caused by the diabetic oxidative stress stimulating macrophages and other inflammatory cells to secrete cytokines as interleukin 1  $\beta$  & tumour necrotic factor (TNF), and NO which affect both steroidogenesis and spermatogenesis (75,95) in addition to the metabolic disturbances due to insulin deficiency (96).

In the present study, it was found that exogenous administration of ghrelin was associated with marked improvement in testicular histoarchitecture of diabetic rats together with significant recovery in the testicular weight. These findings could be attributed to the antioxidant properties of this peptide as was proved in the present study together with maintenance of nearly normal levels of LH, FSH, testosterone, glucose & insulin.

One of outstanding features of the present study was the observation that exogenous ghrelin administration in normal control rats produced no changes in testicular histoarchitecture together with insignificant changes in serum FSH, LH & testosterone levels and insignificant changes in epididymal sperm count & motility. However, it resulted in a significant increase in both testicular weight & testicular antioxidant enzymes activities but a significant decrease in testicular MDA level.

These results are in agreement with those of many investigators who reported that chronic administration of ghrelin a) tended to increase

testicular weight in fed animals without any significant change in plasma levels of sex hormones (97), b) increased the integrity of sperm membrane, but the sperm motility and concentration did not display any alterations (98), c) had antioxidant effects in rat testes (51), but in contrast to those of others who demonstrated that systemic administration of ghrelin reduced the GnRH pulse frequency in rats that is mediated by NPY and completely abolished by the NPY-Y5 receptor antagonist (99), and those who concluded that, ghrelin can suppress both LH and FSH secretion in both male and female rats and humans (100,101,102).

It seems that the effects of ghrelin clearly depends on the nutritional state as it was found that while ghrelin administration in fed rats did not induce detectable changes in plasma levels of gonadotropins and testosterone, in food-restricted animals, where endogenous ghrelin levels are known to be increased (103), it was found that chronic administration of ghrelin induced overt decreases in plasma LH and testosterone levels (97) and, such a state of suppression is produced by the massive hyper-ghrelinemia induced by the combined increase of endogenous ghrelin in calorie-restricted animals plus the exogenous administration of the peptide (104). This observation is in agreement with previous reports showing a predominant inhibitory effect of high doses of ghrelin on LH and testosterone secretion in male rats (36,105). Moreover, *Antonyselvi et al.* (53) emphasized that ghrelin suppresses different stages of spermatogenesis in normal albino rats in a dose dependent manner and that this suppression was more pronounced at a dose of 20µg/kg of body weight.

The discrepancy between our results and those of others may be due to differences in the chosen dose, route of administration, duration of administration, species difference and / or nutritional status.

**In conclusion:** While ghrelin produces no significant alteration in testicular function in normal rats, it restored the testicular functions including steroidogenesis and spermatogenesis in STZ-diabetic rats to become nearly normal. The probable mechanisms of action of this peptide might be via 1) decreasing the lipid peroxidation as evidenced by reduction in MDA levels and by increasing the antioxidant enzymes SOD, CAT and GPx activities in the testes. 2) increasing LH, FSH & testosterone levels. 3) improving carbohydrate metabolism as evidenced by significant decrease in serum glucose which was accompanied by significant increase in serum

insulin levels. All these mechanisms may be due to the antioxidant properties of this peptide at different levels such as hypothalamus, pituitary, testes and pancreas.

Further studies are required to investigate the use of ghrelin as a potential protective target for the hypothalamo-pituitary-testicular axis dysfunction in diabetics.

#### Acknowledgment:

To Prof. / **Kamal EL-Kashish**, pathology department-Medicine, Zagazig University for performing the histological study and to Prof. / **Somiaa Hasan** Biochemistry department-Medicine, Zagazig University for performing the laboratory tests.

#### REFERENCES:

1. *Sozmen EY, Sozmen B, Delen Y et al. (2001):* Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. *Arch. Med. Res.*, 4: 283–287.
2. *Hakeem P, Sani H.A and Noor M.M. (2008):* Effects of *Gynura procumbens* extract and glibenclamide on sperm quality and specific activity of testicular lactate dehydrogenase in streptozotocin – induced diabetic rats. *Malaysian J. Biochemistry and Molecular biology*, 16: 10-14.
3. *Mohasseb M, Ebied S, Yehia M.A et al. (2011):* Testicular oxidative damage and role of combined antioxidant supplementation in experimental diabetic rats. *Journal of Physiology and Biochemistry*, 67: 185–194.
4. *Alves M, Martins A, Rato L, et al. (2013):* Molecular mechanisms beyond glucose transport in diabetes-related male infertility. *Biochim. Biophys. Acta*, 1832: 626–635.
5. *Dhindsa S, Prabhakar S, Sethi M, et al. (2004):* Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, 89:5462–5468.
6. *Olivares A, Méndez J.P, Cárdenas M, et al. (2009):* Pituitary–testicular axis function, biological to immunological ratio and charge isoform distribution of pituitary LH in male rats with experimental diabetes. *General and Comparative Endocrinology*, 161: 304–312.
7. *Nah W.H, Koh K, Ahn H.S, et al. (2012):* Effect of *Spirulina maxima* on spermatogenesis and steroidogenesis in streptozotocin-induced type I diabetic male rats. *Food Chemistry*, 134: 173–179.
8. *Idris M.H, Budin S.B, Osman M, et al. (2012):* protective role of hibiscus sabdariffa calyx extract against streptozotocin induced

- sperm damage in diabetic rats. *EXCLI Journal*, 11:659-669.
9. Agbaje I.M, Rogers D.A, McVicar C.M, et al. (2007): Insulin dependent diabetes mellitus: implications for male reproductive function. *Hum. Reprod.*, 22 : 1871–1877.
  10. Padron R.S, Dambay A, Suarez R, et al. (1984): Semen analyses in adolescent diabetic patients. *Acta Diabetol. Lat.*, 21: 115–121.
  11. Makker K, Agarwal A and Sharma R. (2009): Oxidative stress and male infertility. *Indian J. Med. Res.*, 129: 357-367.
  12. Akondi R.B, Kumar P, Annapurna A, et al. (2011): Protective Effect of Rutin and Naringin on Sperm Quality in Streptozotocin (STZ) Induced Type 1 Diabetic Rats. *Iranian Journal of Pharmaceutical Research*, 10 (3): 585-596.
  13. Evans J.L, Goldfine I.D, Maddux B.A, et al. (2002): Oxidative stress and stress activated signaling pathways: A unifying hypothesis of type 2 diabetes. *Endo. Rev.*, 23: 599-622.
  14. Park N.C, Park H.J, Lee K.M, et al. (2003): Free radical scavenger effect of rebamipide in sperm processing and cryopreservation. *Asian J. Androl.*, 5: 195-201.
  15. Aybek H, Aybek Z, Rota S, et al. (2008): The effects of diabetes mellitus, age, and vitamin E on testicular oxidative stress. *Fertil. Steril.*, 90:755–60.
  16. Khaki A, Nouri M, Fathiazad F, et al. (2010): Beneficial effects of quercetin on sperm parameters in streptozotocin-induced diabetic male rats. *Phytother Res.*, 24(9):1285-1291.
  17. Kojima M, Hosoda H, Date Y, et al. (1999): Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature*, 402: 656–660.
  18. Lim C.T, Kola B, Feltrin D, et al. (2013): Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. *Molecular and Cellular Endocrinology*, 365: 303–308.
  19. Tschop M, Wawarta R, Riepl RL, et al. (2001): Post-prandial decrease of circulating human ghrelin levels. *J. Endocrinol. Invest.*, 24: 19–21.
  20. Banks K.A and Murphy K.G. (2013): Role of ghrelin in glucose homeostasis and diabetes. *Diabetes Management*, 3(2): 171-182.
  21. Arnes L, Hill JT, Gross S, et al. (2012): Ghrelin Expression in the Mouse Pancreas Defines a Unique Multipotent Progenitor Population. *PLoS ONE*, 7: 52026.
  22. Cowley M.A, Smith R.G, Diano S, et al. (2003): The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuron*, 37: 649–661.
  23. Korbonits M, Kojima M, Kangawa K, et al. (2001): Presence of ghrelin in normal and adenomatous human pituitary. *Endocrine*, 14: 101–104.
  24. Tena-Sempere M, Barreiro M.L, Gonzalez L.C, et al. (2002): Novel expression and functional role of ghrelin in rat testis. *Endocrinology*, 143: 717–725.
  25. Dezaki K. (2013): Ghrelin Function in Insulin Release and Glucose Metabolism. *Endocr. Dev.*, 25: 135–143.
  26. Date Y, Nakazato M, Hashiguchi S, et al. (2002): Ghrelin is present in pancreatic B-cells of humans and rats and stimulates insulin secretion. *Diabetes*, 51:124–129.
  27. Granata R, Baragli A, Settanni F, et al. (2012): Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. *J. Mol. Endocrinol.*, 45: 107–118.
  28. Zwirska-Korczala K, Adamczyk-Sowa M, Sowa P, et al. (2007): Role of leptin, ghrelin, angiotensin II and orexins in 3 T3 L1 preadipocyte cells proliferation and oxidative metabolism. *J. Physiol. Pharmacol.*, 58: 53-64.
  29. Kheradmand A, Alirezaei M and Birjandi M. (2010): Ghrelin promotes antioxidant enzyme activity and reduces lipid peroxidation in the rat ovary. *Regulatory Peptides*, 162: 84–89.
  30. Çetin E, Kanbur M, Çetin N, et al. (2011): Hepatoprotective effect of ghrelin on carbon tetrachloride-induced acute liver injury in rats. *Regulatory Peptides*, 171 : 1–5
  31. Coskun Z.M, Sacanc O, Karatugd A, et al. (2013): Regulation of oxidative stress and somatostatin, cholecystokinin, apelin gene expressions by ghrelin in stomach of newborn diabetic rats. *ACTHIS*, 115(7): 707-714.
  32. Tsuchimochi W, Kyoraku I, Yamaguchi H, et al. (2013): Ghrelin prevents the development of experimental diabetic neuropathy in rodents. *European Journal of Pharmacology*, 702 : 187–193
  33. Kheradmand A, Dezfoulian O and Tarrahi M.J. (2011): Ghrelin attenuates heat-induced degenerative effects in the rat testis. *Regulatory Peptides*, 167: 97–104.
  34. Taati M, Moghadasi M, Dezfoulian O, et al. (2012): The effect of ghrelin pretreatment

- on epididymal sperm quality and tissue antioxidant enzyme activities after testicular ischemia/reperfusion in rats. *Journal of physiology and biochemistry*, 68: 91-97.
35. Ates O, Cayli S.R, Yucel N, et al. (2007): Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. *J. Clin. Neurosci.*, 14(3): 256-260.
  36. Fernandez-Fernandez R, Navarro VM, Barreiro ML, et al. (2005): Effects of chronic hyperghrelinemia on puberty onset and pregnancy outcome in the rat. *Endocrinology*, 146:3018-3025.
  37. Wren A.M, Small C.J, Thomas E.L, et al. (2001): Ghrelin causes hyperphagia and obesity in rats. *Diabetes*, 50:2540-2547.
  38. Schlorff E.C, Husain K and Somani S.M. (1999): Dose and Time Dependent Effects of Ethanol on Antioxidant System in Rat Testes. *Alcohol*, 18: 203-214.
  39. Tietz N.W. (1995): Clinical Guide to Laboratory Tests, 3rd Ed., W.B. Saunders Company, Philadelphia, 509-580.
  40. Temple R.C, Clark P.M and Hales C.N (1992): Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. *Diabetic Medicine*, 9: 503-512.
  41. Rebar R.W, Morandini I.C, Petze J.E, et al. (1982): Hormonal basis of reproductive defects in athymic mice: reduced gonadotropins and testosterone in males. *Biol. Repro.*, 5: 1267-1276.
  42. Kakkar P, Das B and Viswanathan P.N. (1984): A modified spectrophotometric assay of superoxide dismutase. *Indian J. Biochem. Biophys.*, 21: 130- 132.
  43. Luck H. (1974): In: Methods in Enzymatic Analysis. Academic Press. 2: 885-890.
  44. Reddy K.P, Subhani S.M, Khan P.A and Kumar K.B. (1995): Effect of light and benzyl adenine on dark-treated growing rice leaves, II changes in peroxidase activity. *Plant cell physiol.*, 24: 987-994.
  45. Ohkawa H, Ohishi N and Yagi K. (1979): Assay for lipid peroxides in animals and tissue by thiobarbituric acid reaction. *Anal. Biochem.*, 95: 351-358.
  46. Belsey M.A, Moshissi K.S, Eliasson R, et al. (1980): Laboratory manual for the examination of human semen and semen cervical mucus interaction. *Press concern*, 1-43
  47. Annunziata L, Domenico F and Pietro T. (2005): Glyco-oxidation in diabetes and related diseases. *Clin. Chim. Acta*, 2: 236-50.
  48. Saalu LC. (2010): The incriminating role of reactive oxygen species in idiopathic male infertility: an evidence based evaluation. *Pak. J. Biol. Sci.*, 13: 413-22.
  49. Kojima M and Kangawa K. (2005): Ghrelin: Structure and Function. *Physiol Rev.*, 85: 495-522.
  50. Celi F, Bini V, Papi F, et al. (2005): Circulating acylated and total ghrelin and galanin in children with insulin-treated type 1 diabetes: relationship to insulin therapy, metabolic control and pubertal development. *Clin. Endocrinol.*, 63(2):139-145.
  51. Kheradmand A, Alirezaei M, Asadian P, et al. (2009): Antioxidant enzyme activity and MDA level in the rat testis following chronic administration of ghrelin. *Andrologia.*, 41(6):335-340.
  52. Alison M, Caroline J, Caroline R, et al. (2001): Ghrelin Causes Hyperphagia and Obesity in Rats. *Diabetes*, 50: 2540-2547.
  53. Antonyselvi S, Raja Kumar D, Shanthi P., et al. (2012): Effect of intraperitoneal administration of Ghrelin hormone in testis of immature and mature male albino rats to study histoarchitecture. *Int. J. Pharm. Biomed. Res.*, 3(2):85-89.
  54. Kamegai J, Tamura H, Shimizu T, et al. (2000): Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. *Endocrinology*, 141:4797- 4800.
  55. Wren AM, Small CJ, Ward HL, et al. (2000): The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. *Endocrinology*, 141:4325- 4328.
  56. Warzecha Z, Dembinski A, Ceranowicz P, et al. (2006): Influence of ghrelin on gastric and duodenal growth and expressing of digestive enzymes in young mature rats. *J. Physiol. Pharmacol.*, 57: 425-37.
  57. Banks W.A, Tschop M, Robinson S.M, et al. (2002): Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. *J. Pharmacol. Exp. Ther.*, 302: 822-827.
  58. Banks W.A, Burney B.O and Robinson S.M. (2008): Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. *Peptides*, 29: 2061-2065.
  59. Chen H.Y, Trumbauer M.E, Chen A.S, et al. (2004): Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and

- agouti-related protein. *Endocrinology*, 145: 2607–2612.
60. Toshinai K, Date Y, Murakami N, et al. (2003): Ghrelin induced food intake is mediated via the orexin pathway. *Endocrinology*, 144:1506-1512.
  61. Faulconbridge L.F, Cummings D.E, Kaplan J.M, et al. (2003): Hyperphagic effects of brainstem ghrelin administration. *Diabetes*, 52: 2260-2265.
  62. Choi K, Roh S.G, Hong Y.H, et al. (2003): The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. *Endocrinology*, 144:754-759.
  63. Kim M.S, Yoon C.Y, Jang P.G, et al. (2004): The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. *Mol. Endocrinol.*, 18: 2291-2301.
  64. Muccioli G, Pons N, Ghe C, et al. (2004): Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. *Eur. J. Pharmacol.*, 498: 27-35.
  65. Rocha-Sousa A, Tavares-Silva M, Fonseca S, et al. (2010): Diabetes, Ghrelin And Related Peptides: From Pathophysiology to Vasculopathy. *The Open Circulation and Vascular Journal*, 3:17-29
  66. Shrilatha B and Muralidhara. (2007): Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: Its progression and genotoxic consequences. *Reprod. Toxicol.*, 23: 578-587.
  67. Tavridou A, Unwin N.C, Laker M.F, et al. (1997): Serum concentrations of vitamin A and E in impaired glucose tolerance. *Clin. Chim. Acta*, 266: 129–140.
  68. Irako T, Akamizu T, Hosoda H, et al. (2006): Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. *Diabetologia*, 49:1264–1273.
  69. Turk N, Kaya Dağistanli F, Sacanb O, et al. (2011): Obestatin and insulin in pancreas of newborn diabetic rats treated with exogenous ghrelin. *Acta Histochemica*, 114(4):349-357.
  70. Kerem M, Salman B, Özsoy S, et al. (2009): Exogenous ghrelin enhances endocrine and exocrine regeneration in pancreatectomized rats. *Journal of Gastrointestinal Surgery*, 13: 775–783.
  71. Sun Y, Butte N.F, Garcia J.M, et al. (2008): Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. *Endocrinology*, 149(2): 843-850.
  72. Ahrens B. (2012): Antibodies in metabolic diseases. *New Biotechnology*, 28:530-537.
  73. Granata R, Volante M, Settanni F, et al. (2010): Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. *J. Mol. Endocrinol.*, 45: 9–17.
  74. Kheyabany S.K, Nabavizadeh F, Vaezi G.H, et al. (2013): Protective Effect of Ghrelin on Isoniazid-induced Liver Injury in Rat. *Journal of Stress Physiology & Biochemistry*, 9: 273-282.
  75. Baccetti B, La Marca A, Piomboni P, et al. (2002): Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality. *Hum.Reprod.*, 17(10):2673-2677.
  76. Ballester J, Munoz M.C, Dominguez J, et al. (2004): Insulin-dependent diabetes affects testicular function by FSH- and LH-linked mechanisms. *J. Androl.*, 25: 706–719.
  77. Kim S.T and Moley K.H. (2008): Paternal effect on embryo quality in diabetic mice is related to poor sperm quality and associated with decreased glucose transporter expression. *Reproduction*, 136:313–322.
  78. Niewoehner C.B. (2004): Endocrine pathophysiology. *Raleigh, NC: Hayes Barton Press*, 232-240.
  79. Salvi R, Castillo E, Voirol M.J, et al. (2006): Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen activated protein kinase pathway. *Endocrinology*, 147: 816–826.
  80. Herbison A.E (1997): Noradrenergic regulation of cyclic GnRH secretion. *Reviews in Reproduction*, 2:1–6.
  81. Soudamani S, Yuvaraj S, Malini T, et al. (2005): Experimental diabetes has adverse effects on the differentiation of ventral prostate during sexual maturation of rats. *Anat. Rec.*, 287: 1281-1289.
  82. Buggs C, Weinberg F, Kim E, et al. (2006): Insulin augments GnRH-stimulated LH beta gene expression by Egr-1. *Molecular and Cell. Endocrinol.*, 249:99–106.
  83. Granado M, Chowen J.A, García-Cáceres C, et al. (2009): Ghrelin treatment protects lactotrophs from apoptosis in the pituitary of diabetic rats. *Mol. Cell. Endocrinol.*, 309, 67–75.
  84. Niven M.J, Hitman G.A and Badenoch D.F. (1995): A study of spermatozoal motility in type 1 diabetes mellitus. *Diabet. Med.*, 12: 921–924.

85. Shamsi MB, Kumar R, Bhatt A, et al. (2008): Mitochondrial DNA mutations in etiopathogenesis of male infertility. *Indian J. Urol.*, 24: 150-154.
86. Gobbo MG, Ribeiro DL, Taboga SR, et al. (2012): Oxidative stress markers and apoptosis in the prostate of diabetic rats and the influence of vitamin C treatment. *J. Cell Biochem.*, 113:2223-2233.
87. Silva P.N and Gadella B.M. (2006): Detection of damage in mammalian sperm cells. *Theriogenology*, 65: 958-978.
88. Hamden K, Jaouadi B, Carreau S, et al. (2010): Potential protective effect on key steroidogenesis and metabolic enzymes and sperm abnormalities by fenugreek steroids in testis and epididymis of surviving diabetic rats. *Arch Physiol. Biochem.*, 116:146-155.
89. La Vignera S, Condorelli R, Vicari E, et al. (2012): Diabetes mellitus and sperm parameters. *J. Androl.*, 33:145-153.
90. Kheradmand A, Taati M and Babaei H. (2009): Ghrelin enhances viability of rat spermatozoa during incubation at 37°C. *Iranian Journal of Veterinary Research*, 10(2):103-109.
91. Lukaszuk A, Kotwicka M, Jankowska A, et al. (2012): Expression of ghrelin receptor (GHSR-1a) in rat epididymal spermatozoa and the effects of its activation. *reproductive biology*, 12: 293 – 300
92. Kyathanahalli C, Bangalore S, Hanumanthappa K, et al. (2013): Experimental diabetes-induced testicular damage in prepubertal rats. *Journal of Diabetes*. doi: 10.1111/1753-0407.12068. [Epub ahead of print].
93. Holdcraft RW and Braun RE. (2004): Androgen receptor function is required in Sertoli cells for the terminal differentiation of haploid spermatids. *Development*, 131(2):459-467.
94. Garcia M.C, Lopez M, Alvarez C.V, et al. (2007): Role of ghrelin in reproduction. *Reproduction*, 133:531-540.
95. Abd El Samad A.A. (2013): Role of Aminoguanidine on the Testis of Streptozotocin-Induced Diabetic Albino Rat, A Light and Electron Microscopic Study. *J. Histol.*, 33: 451 – 466.
96. Bal R, Türk G, Tuzcu M, Yilmaz O, et al. (2011): Protective effects of nanostructures of hydrated C60 fullerene on reproductive function in streptozotocin-diabetic male rats. *Toxicology*, 282:69-81.
97. Sirotkin A.V, Chrenkova M, Nitrayova S, et al. (2008): Effects of chronic food restriction and treatments with leptin or ghrelin on different reproductive parameters of male rats. *Peptides*, 29: 1362 – 1368.
98. Kheradmand A, Taati M and Babaei H. (2009): The effects of chronic administration of ghrelin on rat sperm quality and membrane integrity. *Animal Biology*, 59(2):159-168.
99. Lebrethon M.C, Aganina A, Fournier M, et al. (2007): Effects of in vivo and in vitro administration of ghrelin, leptin and neuropeptide mediators on pulsatile gonadotrophin-releasing hormone secretion from male rat hypothalamus before and after puberty. *J. Neuroendocrinol.*, 19:181-188.
100. Fernandez-Fernandez R, Tena-Sempere M, Roa J, et al. (2007): Direct stimulatory effect of ghrelin on pituitary release of LH through a nitric oxide-dependent mechanism that is modulated by estrogen. *Reproduction*, 133:1223-1232.
101. Vulliamoz N.R, Xiao E, Xia-Zhang L, et al. (2008): Astressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkey. *Endocrinology*, 149: 869-874.
102. Lanfranco F, Bonelli L, Baldi M, et al. (2008): Acylated ghrelin inhibits spontaneous LH pulsatility and responsiveness to naloxone, but not that to GnRH in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. *J. Clin. Endocrinol. Metab.*, 93: 3633-3639.
103. Tena-Sempere M. (2007): Roles of ghrelin and leptin in the control of reproductive function. *Neuroendocrinology*, 86: 229-41.
104. Yang H, Youm Y.H, Nakata C, et al. (2007): Chronic caloric restriction induces forestomach hypertrophy with enhanced ghrelin levels during aging. *Peptides*, 28: 1931-1936.
105. Fernández-Fernández R, Tena-Sempere M, Navarro V.M, et al. (2005): Effects of ghrelin upon gonadotropin-releasing hormone and gonadotropin secretion in adult female rats: in vivo and in vitro studies. *Neuroendocrinology*, 82:245-255.

### تأثير الجريلين على وظائف الخصية في الجرذان المصابة بالنوع الأول من داء السكري المحدث بستربتوزوتوسين

- ◆ يعد داء السكري أكثر أمراض التمثيل الغذائي شيوعاً وله العديد من المضاعفات التي قد تنشأ بسبب زيادة اجهاد الأوكسدة المتمثل في زيادة الشوارد الحرة وأكسيد النيتريك وبعض السيوكينات مع نقص في نشاط الانزيمات المضادة للأوكسدة. وقد تضاربت الدراسات حول تأثيره على المحور التحت مهدي-النخامي-الخصوى وعلى معدل الخصوبة.
- ◆ وفي السنوات القليلة الماضية اكتشف العلماء هرمونا جديداً يسمى جريلين وهو عبارة عن بيبتيدي يفرز من المعدة وله العديد من الأنشطة الأيضية والعصبية بجانب تأثيره على الغدد الصماء. إلا أن الأبحاث أثبتت أيضاً أنه يفرز في أماكن أخرى كثيرة من الجسم وله مستقبلات بها مثل منطقة تحت المهاد، الغدة النخامية، الخصية والبنكرياس.
- ◆ هذا ولقد لاحظ كثير من العلماء أن مستويات جريلين تقل في البلازما في النوع الأول من داء السكري كما تضاربت الأبحاث حول تأثيره على افراز الأنسولين وتوازن مستوى الجلوكوز في الدم، ومما هو جدير بالذكر أن الدراسات الحديثة أثبتت أن له دوراً مضاداً للأوكسدة.

#### الهدف من البحث

أجريت هذه الدراسة لاستكشاف التأثير المحتمل لهرمون جريلين على المحور النخامي-الخصوى في الجرذان السليمة والمصابة بداء السكري من النوع الأول المحدث تجريبياً بالحقن البريتوني لمادة ستربتوزوتوسين وكذلك كمحاولة لتوضيح بعض الآليات المحتملة لهذا التأثير.

#### مواد وطرق البحث

- ◆ أجريت هذه الدراسة على ٣٢ من ذكور الجرذان البيضاء السليمة البالغة والتي تزن من ١٧٠-١٩٥ جم وقد تم تقسيمها إلى ٤ مجموعات :
  - ◆ المجموعة ( الأولى أ ) : مجموعة سليمة ضابطة (بدون علاج) حقنت تحت الجلد مرة واحدة كل يومين بمحلول ملحي تركيزه ٠.٩ % بجرعة قيمتها ١٠٠ ميكروليتر لكل جرذ لمدة ٣٠ يوم.
  - ◆ المجموعة (الأولى ب) : مجموعة سليمة حقنت تحت الجلد مرة واحدة كل يومين بجريلين بجرعة قيمتها ٢ نانومول مذابة في ١٠٠ ميكروليتر محلول ملحي تركيزه ٠.٩ % لكل جرذ لمدة ٣٠ يوم.
  - ◆ المجموعة (الثانية أ) : مجموعة مصابة بالنوع الأول من داء السكري المحدث تجريبياً بعقار ستربتوزوتوسين بجرعة قيمتها ٦٠ ميلي جرام/كيلوجرام من وزن الجسم مذابة في ١٠٠ ميكروليتر محلول ملحي تركيزه ٠.٩ % حقنت في الغشاء البريتوني مرة واحدة.
  - ◆ المجموعة (الثانية ب) :مجموعة مصابة بالسكري حقنت تحت الجلد مرة واحدة كل يومين بجريلين بجرعة قيمتها ٢ نانومول مذابة في ١٠٠ ميكروليتر محلول ملحي تركيزه ٠.٩ % لكل جرذ في لمدة ٣٠ يوم.
- هذا وقد تم وزن الجرذان ثم جمع عينات الدم من حزمة الأوردة خلف العين في نهاية فترة حقن الجريلين ( ٣٠ يوماً ) ، ثم تم فصل المصل من كل عينة وحفظه مجمداً في درجة ٢٠<sup>o</sup> مئوية تحت الصفر لحين استخدامه في قياس الجلوكوز، الأنسولين ، هرمون اللوتنة (LH) ، الهرمون المحفز لجريبات المبيض (FSH) وهرمون التستوستيرون كما تم أيضاً إستئصال الخصية بالبربخ حيث استخدم البربخ لتقييم الحيوانات المنوية من حيث العدد والحركة بينما تم وزن الخصى واستخدام الخصية اليمنى لعمل شرائح منها لفحصها بالميكروسكوب الضوئي بعد صبغها بصبغات الهيماتوكسيلن والأويسين بينما استخدمت الخصية اليسرى لقياس تركيز مادة مالون داي ألدهيد وقياس نشاط انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز المضادة للأوكسدة.

#### نتائج البحث

- ◆ لقد أوضحت مجموعة الحيوانات المصابة بالنوع الأول من داء السكري المحدث تجريبياً بستربتوزوتوسين (المجموعة الثانية أ) عند مقارنتها بالمجموعة السليمة الضابطة (المجموعة الأولى أ) حدوث:
  - نقص ذى دلالة إحصائية في وزن الجسم، وزن الخصية ، مستويات هرمون الانسولين ، هرمون اللوتنة ، الهرمون المحفز لجريبات المبيض ،هرمون التستوستيرون ، عدد الحيوانات المنوية بالبربخ وحركتها و أنشطة انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز بأنسجة الخصية .
  - زيادة ذات دلالة إحصائية في مستوى الجلوكوز بمصل الدم و مستوى مالون داي ألدهيد بأنسجة الخصية.
  - تغير ملحوظ في حجم و شكل أنابيب الخصية والتي اصطفت بقليل من الخلايا مع زيادة ملحوظة في سمك الغشاء القاعدي وذلك عند فحصها مجهرياً.
- ◆ كما أوضحت النتائج أن حقن جريلين في المجموعة المصابة بالسكري (المجموعة الثانية ب) عند مقارنتها بالمجموعة المصابة بداء السكري والغير معالجة بجريلين (المجموعة الثانية أ) أدى الى:
  - زيادة ذات دلالة إحصائية في وزن الجسم، وزن الخصية ، مستويات هرمون الانسولين ،هرمون اللوتنة ، الهرمون المحفز لجريبات المبيض ،هرمون التستوستيرون بمصل الدم، عدد الحيوانات المنوية بالبربخ وحركتها و أنشطة انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز بأنسجة الخصية .
  - نقص ذى دلالة إحصائية في مستوى الجلوكوز بمصل الدم و مستوى مالون داي ألدهيد بأنسجة الخصية .
  - تحسن ملحوظ في نسيج الخصية وذلك عند فحصها مجهرياً.
- ◆ ومما هو جدير بالملاحظة في هذه الدراسة أن حقن الجريلين في المجموعة السليمة (المجموعة الأولى ب) عند مقارنتها بالمجموعة السليمة الغير معالجة بجريلين (المجموعة الأولى أ) أدى الى:
  - عدم وجود أى تغير ذا دلالة إحصائية في مستويات الجلوكوز،هرمون الانسولين ،هرمون اللوتنة ، الهرمون المحفز لجريبات المبيض ،هرمون التستوستيرون بمصل الدم ، عدد الحيوانات المنوية بالبربخ وأحركتها و أنشطة انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز بأنسجة الخصية .
  - عدم وجود أى تغير ملحوظ في نسيج الخصية وذلك عند فحصها مجهرياً.
  - زيادة ذات دلالة إحصائية في وزن الجسم، وزن الخصية و أنشطة انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز بأنسجة الخصية .
  - نقص ذى دلالة إحصائية في مستوى مالون داي ألدهيد بأنسجة الخصية .

#### المستخلص من البحث

أنه في حين أن هرمون جريلين لم ينتج أي تغيير ملحوظ في وظيفة الخصية في الجرذان السليمة، فإنه أدى إلى تحسن وظيفة الخصية في الجرذان المصابة بالسكري . و قد يكون ذلك من خلال خفض أكسدة الدهون كما يتضح من انخفاض في مستويات مالون داى ألدهيد و عن طريق زيادة أنشطة انزيمات سوبراوكسيد ديسميوتاز ، كاتالاز وجلوتاثيون بيروكسيداز المضادة للأكسدة في الخصية . هذا جنبا إلى جنب مع زيادة كبيرة في مستويات هرمون اللوتنة ، الهرمون المحفز لجريبات المبيض وهرمون التستوستيرون و أيضا تحسن في التمثيل الغذائي للكربوهيدرات في شكل انخفاض كبير في مستوى السكر يرافقه زيادة كبيرة في مستويات الانسولين في الدم التي قد تكون بدورها بسبب خصائصه المضادة للأكسدة على مختلف المستويات مثل تحت المهاد، الغدة النخامية والبنكرياس.

#### التوصية

من نتائج هذا البحث يمكن أن نوصي بعمل مزيد من الدراسات لبحث امكانية الاستفادة من التأثير الوقائي لهرمون جريلين كمضادا للأكسدة على الخلل الوظيفي للمحور التحت مهادى-النخامى-الخصوى فى مرضى السكري.